Alzheimer's disease and n-3 polyunsaturated fatty acids: Beneficial effects and possible molecular pathways involved

Current Signal Transduction Therapy

Volumn 3, Issue 3, 2008, Pages 152-157

  Calviello, Gabriella ^a   Serini, Simona ^a   Piccioni, Elisabetta ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Alzheimer's disease; DHA; EPA; N 3 PUFAs; Signal transduction

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; DOCOSAPENTAENOIC ACID; HYDROXYICOSATETRAENOIC ACID; HYPOXIA INDUCIBLE FACTOR 1ALPHA; ICOSANOID; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LEUKOTRIENE; LIPOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE; OMEGA 3 FATTY ACID; PLACEBO; PRESENILIN 1; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; SECRETASE; THROMBOXANE; TUMOR NECROSIS FACTOR ALPHA;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTIFICIAL MILK; BREAST FEEDING; CELL FUNCTION; CELL MEMBRANE FLUIDITY; CELL MEMBRANE PERMEABILITY; CELL SURVIVAL; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CYTOKINE PRODUCTION; DEGENERATIVE DISEASE; DEMENTIA; DISEASE MODEL; ENZYME REGULATION; EPIDEMIOLOGICAL DATA; FISH; FOOD INTAKE; GENE EXPRESSION; GENE MUTATION; HUMAN; LEARNING DISORDER; LIPID RAFT; MEDICAL RESEARCH; MENTAL DEVELOPMENT; MOLECULAR MECHANICS; NERVE CELL; NERVE CELL DEGENERATION; NONHUMAN; NUTRITIONAL DEFICIENCY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK REDUCTION; TRANSGENIC MOUSE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 54849422618     PISSN: 15743624     EISSN: None     Source Type: Journal    
DOI: 10.2174/157436208785699659     Document Type: Review

References (105)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Alzheimer's Disease International. Lancet 2005; 366: 2112-7.
2. World Health Organization. World Health Report 2003 - Shaping the future. Geneva WHO, 2003.
3. Cummings JL, Cole G. Alzheimer disease. JAMA 2002; 287: 2335-8.
4. Jellinger KA, Bancher C. Neuropathology of Alzheimer's disease: a critical update. J Neural Transm Suppl 1998; 54: 77-95.
5. Giacobini E. Cholinesterases: new roles in brain function and in Alzheimer's disease. Neurochem Res 2003; 28: 515-22.
6. Conway KA, Baxter EW, Felsenstein KM, Reitz AB. Emerging beta-amyloid therapies for the treatment of Alzheimer's disease. Curr Pharm Des 2003; 9: 427-47.
7. Pangalos MN, Jacobsen SJ, Reinhart PH. Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide. Biochem Soc Trans 2005; 33: 553-8.
8. Jacobsen JS. Alzheimer's disease: an overview of current and emerging therapeutic strategies. Curr Top Med Chem 2002; 2: 343-52.
9. Neuringer M, Anderson GJ, Connor WE. The essentiality of n-3 fatty acids for the development and function of the retina and brain. Annu Rev Nutr 1988; 8: 517-541.
10. Morris MC. Docosahexaenoic acid and Alzheimer disease. Arch Neurol 2006; 63: 1527-8.
11. Saugstad LF. Are neurodegenerative disorder and psychotic manifestations avoidable brain dysfunctions with adequate dietary omega-3? Nutr Health 2006; 18: 89-101.
12. Alessandri JM, Guesnet P, Vancassel S, et al. Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. Reprod Nutr Dev 2004; 44: 509-38.
13. Johnson EJ, Schaefer EJ. Potential role of dietary n-3 fatty acids in the prevention of dementia and macular degeneration. Am J Clin Nutr 2006; 83: 1494S-1498S.
14. Breckenridge WC, Gombos G, Morgan IG. The lipid composition of adult rat brain synaptosomal plasma membranes. Biochim Biophys Acta 1972; 266: 695-707.
15. Salem N Jr, Litman B, Kim HY, Gawrisch K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36: 945-59.
16. Burdge GC. Metabolism of alpha-linolenic acid in humans. Prostaglandins Leukot Essent Fatty Acids 2006; 75: 161-8.
17. Pawlosky RJ, Hibbeln JR, Novotny JA, Salem N Jr. Physiological compartmental analysis of alpha-linolenic acid metabolism in adult humans. J Lipid Res 2001; 42: 1257-1265.
18. Jones PJH, Papamandjaris AA. Lipids: cellular metabolism. In: Bowen BA, Russell RM, eds. Present knowledge in nutrition. 8th ed. Washington, DC: ILSI Press, 2001.
19. von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. Cardiovasc Res 2007; 73: 310-5.
20. Friedland RP. Fish consumption and the risk of Alzheimer disease: is it time to make dietary recommendations? Arch Neurol 2003; 60: 923-4.
21. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam Study. Ann Neurol 1997; 42: 776-82.
22. Barberger-Gateau P, Letenneur L, Deschamps V, Peres K, Dartigues JF. Renaud S. Fish, meat, and risk of dementia: cohort study. BMJ 2002; 325: 932-3.
23. Morris MC, Evans DA, Bienias JL, et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003; 60: 940-6.
24. van Gelder BM, Tijhuis M, Kalmijn S, Kromhout D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: the Zutphen Elderly Study. Am J Clin Nutr 2007; 85: 1142-7.
25. Soderberg M, Edlund C, Kristensson K, Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991; 26: 421-5.
26. Conquer JA, Tierney MC, Zecevic J, Bettger WJ, Fisher RH. Fatty acid analysis of blond plasma of patients with Alzheimer's disease, other types of dementia, and cognitive impairment. Lipids 2000; 35: 1305-12.
27. Schaefer EJ, Bongard V, Beiser AS, et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham Heart Study. Arch Neurol 2006; 63: 1545-50.
28. Heude B, Ducimetiere P, Berr C; EVA Study. Cognitive decline and fatty acid composition of erythrocyte membranes-The EVA Study. Am J Clin Nutr 2003; 77: 803-8.
29. Tully AM, Roche HM, Doyle R, et al. Low serum cholesteryl ester-docosahexaenoic acid levels in Alzheimer's disease: a case-control study. Br J Nutr 2003, 89: 483-9.
30. Lannfelt L. Genetics of Alzheimer's disease. Acta Neurol Scand Suppl 1996; 168: 25-7.
31. Takeuchi A, Irizarry MC, Duff K, et al. Age-related amyloid beta deposition in transgenic mice overexpressing both Alzheimer mutant presenilin 1 and amyloid beta precursor protein Swedish mutant is not associated with global neuronal loss. Am J Pathol 2000; 157: 331-9.
32. Jankowsky JL, Fadale DJ, Anderson J, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase Hum Mol Genet 2004; 13: 159-70.
33. Oddo S. Caccamo A, Shepherd JD, et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003; 39: 409-21.
34. Hashimoto M, Hossain S, Shimada T, et al. Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rat. J Neurochem 2002; 81: 1084-91.
35. Calon F, Lim GP, Morihara T, et al. Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease. Eur J Neurosci 2005; 22: 617-26.
36. Cole GM, Frautschy SA. Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model. Nutr Health 2006; 18: 249-59.
37. Calon F, Lim GP, Yang F, et al. Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model. Neuron 2004; 43: 633-45.
38. Lim GP, Calon F, Morihara T, et al. A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model. J Neurosci 2005; 25: 3032-40.
39. Oksman M, Iivonen H, Hogyes E, et al. Impart of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PSI transgenic mice. Neurobiol Dis 2006; 23: 563-72.
40. Green KN, Martinez-Coria H, Khashwji H, et al. Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci 2007; 27: 4385-95.
41. Lukiw WJ, Cui JG, Marcheselli VL, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115: 2774-83.
42. Florent S, Malaplate-Armand C, Youssef I, et al. Docosahexaenoic acid prevents neuronal apoptosis induced by soluble amyloid-beta oligomers. J Neurochem 2006; 96: 385-95.
43. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial. Arch Neurol 2006; 63: 1402-8.
44. Alan DD, Clemens F, Elbourne D, et al. A randomised controlled trial-investigating the effect of n-3 long-chain polyunsaturated fatty acid supplementation on cognitive and retinal function in cognitively healthy older people: the Older People And n-3 Long-chain polyunsaturated fatty acids (OPAL) study protocol [ISRCTN72331636]. Nutr J 2006; 5: 20.
45. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11: S13-21.
46. Treen M, Uauy RD, Jameson DM, Thomas VL, Hoffman DR. Effect of docosahexaenoic acid on membrane fluidity and function in intact cultured Y-79 retinoblastoma cells. Arch Biochem Biophys 1992; 294: 564-70.
47. Valentine RC, Valentine DL. Omega-3 fatty acids in cellular membranes: a unified concept. Prog Lipid Res 2004; 43; 383-402.
48. Meuillet EJ, Wiernsperger N, Mania-Farnell B, Hubert P, Cremel G. Metformin modulates insulin receptor signaling in normal and cholesterol-treated human hepatoma cells (HepG2). Eur J Pharmacol 1999; 377: 241-52.
49. Stillwell W, Wassall SR. Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 2003; 126: 1-27.
50. Michel V, Bakovic M. Lipid rafts in health and disease. Biol Cell 2007; 99: 129-40.
51. London E. Insights into lipid raft structure and formation from experiments in model membranes. Curr Opin Struct Biol 2002; 12: 480-6.
52. Ma DW, Seo J, Switzer KC, et al. n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research. J Nutr Biochem 2004; 15: 700-6.
53. Webb Y, Hermida-Matsumoto L, Resh MD. Inhibition of protein palmitoylation, raft localization, and T cell signaling by 2-bromopalmitate and polyunsaturated fatty acids. J Biol Chem 2000; 275: 261-70.
54. Ma DW, Seo J, Davidson LA, et al. n-3 PUFA alter caveolae lipid composition and resident protein localization in mouse colon. FASEB J 2004; 18: 1040-2.
55. Hattori C, Asai M, Onishi H, et al. BACE1 interacts with lipid raft proteins. J Neurosci Res 2006; 84: 912-7.
56. Riddell DR, Christie G, Hussain I, Dingwall C. Comparmentalization of beta-secretase (Asp2) into low-buoyant density, noncaveolar lipid rafts. Curr Biol 2001; 11: 1288-93.
57. Urano Y, Hayashi I, Isoo N, et al. Association of active gamma-secretase complex with lipid rafts. J Lipid Res 2005; 46: 904-12.
58. Kim SI, Yi JS, Ko YG. Amyloid beta oligomerization is induced by brain lipid rafts. J Cell Biochem 2006; 99: 878-89.
59. Minghetti L, Ajmone-Cat MA, De Berardinis MA, De Simone R. Microglial activation in chronic neurodegenerative diseases: roles of apoptotic neurons and chronic stimulation. Brain Res Brain Res Rev 2005; 48: 251-6.
60. Phillis JW, Horrocks LA, Farooqui AA. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res Rev 2006; 52: 201-43.
61. Lucas SM, Rothwell NJ, Gibson RM. The role of inflammation in CNS injury and disease. Br J Pharmacol 2006; 147: S232-40.
62. Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem 2007; 101: 577-99.
63. Tapiero H, Ba GN, Couvreur P, Tew KD. Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies. Biomed Pharmacother 2002; 56: 215-22.
64. Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, Rao CV. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 2004; 3: 215-21.
65. Hong S, Gronert K, Devchand PR, Moussignac RL, Serhan CN. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood, and glial cells. Autacoids in anti-inflammation. J Biol Chem 2003; 278: 14677-87.
66. Marcheselli VL, Hong S, Lukiw WJ, et al. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 2003; 278: 43807-17.
67. Mills SC, Windsor AC and Knight SC The potential interactions between polyunsaturated fatty acids and colonic inflammatory processes. Clin Exp Immunol 2005; 142:216-228.
68. Yamamoto Y, Gaynor RB. IkappaB kinases: key regulators of the NF-kappaB pathway. Trends Biochem Sci 2004; 29: 72-9.
69. De Caterina R, Massaro M. Omega-3 fatty acids and the regulation of expression of endothelial pro-atherogenic and pro-inflammatory genes. J Membr Biol 2005; 206: 103-16.
70. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 2004; 101: 8491-6.
71. Ariel A, Li PL, Wang W, et al. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem 2005; 280: 43079-86.
72. Serhan CN, Levy B. Novel pathways and endogenous mediators in anti-inflammation and resolution. Chem Immunol Allergy 2003; 83: 115-145.
73. Eckert A, Marques CA, Keil U, Schussel K, Muller WE. Increased apoptotic cell death in sporadic and genetic Alzheimer's disease. Ann N Y Acad Sci 2003; 1010: 604-9.
74. Cole GM, Yang F, Chen PP, Frautschy S, Hsiao K. Caspase activation in dystrophic neurites in Alzheimer's disease and aged HuAPPsw transgenic mice. In Iqbal K, Swaab DF, Winblad B, Wisniewski HM. (Eds), Alzheimer's Disease and Related Disorders. Wiley Chichester UK 1999; 363-369.
75. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 2000; 1: 120-129.
76. Akbar M, Calderon F, Wen Z, Kim HY. Docosahexaenoic acid: a positive modulator of Akt signaling in neuronal survival. Proc Natl Acad Sci USA 2005; 102: 10858-63.
77. Calviello G, Serini S, Palozza P. n-3 polyunsaturated fatty acids as signal transduction modulators and therapeutical agents in cancer. Curr Signal Transduc Ther 2006; 1: 255-271.
78. Calviello G, Palozza P, Piccioni E, et al. Dietary supplementation with eicosapentaenoic and docosahexaenoic acid inhibits growth of Morris hepatocarcinoma 3924A in rats: effects on proliferation and apoptosis. Int J Cancer 1998; 75: 699-705.
79. Calviello G, Di Nicuolo F, Gragnoli S, et al. n-3 PUFAs reduce VEGF expression in human colon cancer cells modulating the COX-2/PGE2 induced ERK-1 and -2 and HIF-1alpha induction pathway. Carcinogenesis 2004; 25: 2303-10.
80. Calviello G, Di Nicuolo F, Serini S, et al. Docosahexaenoic acid enhances the susceptibility of human colorectal cancer cells to 5 fluorouracil. Cancer Chemother Pharmacol 2005; 55: 12-20.
81. Calviello G, Resci F, Serini S, et al. Docosahexaenoic acid induces proteasome-dependent degradation of {beta}-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2. Carcinogenesis 2007; 28: 1202-9.
82. Lee M, Bae MA. Docosahexaenoic acid induces apoptosis in CYP2E1 - containing HepG2 cells by activating the c-Jun N-terminal protein kinase related mitochondrial damage. J Nutr Biochem 2007; 18: 348-54.
83. Brown M, Bellon M, Nicot C. Emodin and DNA potently increase arsenic trioxide interferon-alpha-induced cell death of HTLV-1-transformed cells by generation of reactive oxygen species and inhibition of Akt and AP-1. Blood 2007; 109: 1653-9.
84. Ding Q, Dimayuga E, Keller JN. Oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease. Curr Alzheimer Res 2007; 4: 73-9.
85. Moreira PI, Zhu X, Liu Q, et al. Compensatory responses induced by oxidative stress in Alzheimer disease. Biol Res 2006; 39: 7-13.
86. Grundman M. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr 2000; 71: 630S-636S.
87. Sung S, Yao Y, Uryu K, et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. FASEB J 2004; 18: 323-5.
88. Innis SM. Dietary (n-3) fatty acids and brain development. J Nutr 2007; 137: 855-9.
89. Yavin E, Brand A, Green P. Docosahexaenoic acid abundance in the brain: a biodevice to combat oxidative stress. Nutr Neurosci 2002; 5: 149-57.
90. Kotani S, Sakaguchi E, Warashina S, et al. Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 2006; 56: 159-64.
91. Murray IV, Liu L, Komatsu H, et al. Membrane-mediated amyloidogenesis and the promotion of oxidative lipid damage by amyloid beta proteins. J Biol Chem 2007; 282: 9335-45.
92. Bazan NG. Neuroprotectin D1 (NPD1): a DHA-derived mediator that protects brain and retina against cell injury-induced oxidative stress. Brain Pathol 2005; 15: 159-66.
93. Kitajka K, Puskas LG, Zvara A, et al. The role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc Natl Acad Sci USA 2002; 99: 2619-24.
94. Puskas LG, Kitajka K. Nutrigenomic approaches to study the effects of n-3 PUFA diet in the central nervous system. Nutr Health 2006; 18: 227-32.
95. Kitajka K, Sinclair AJ, Weisinger RS, et al. Effects of dietary omega-3 polyunsaturated fatty acids on brain gone expression. Proc Natl Acad Sci USA 2004; 101: 10931-6.
96. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002; 297: 353-6.
97. Wirths O, Multhaup G, Bayer TA. A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide-the first step of a fatal cascade. J Neurochem 2004; 91: 513-20.
98. Verdier Y, Penke B. Polypeptide and protein aggregates with neurotoxic properties in neurodegenerative disorders: emphasis on beta-amyloid-induced dysfunction of receptor-mediated signal transduction pathways. Curr Signal Transduc Ther 2006, 1, 97-112.
99. Wilquet V, De Strooper B. Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol 2004; 14: 582-8.
100. Zhang J, Ye W, Wang H, Wolfe MS, Greenberg BD, Selkoe DJ. Proteolysis of chimeric beta amyloid precursor proteins containing the Notch transmembrane domain yields amyloid beta-like peptides. J Biol Chem 2002; 277: 15069-75.
101. Coma M, Guix FX, III-Raga G, et al. Oxidative stress triggers the amyloidogenic pathway in human vascular smooth muscle cells. Neurobiol Aging 2007.
102. Todoric J, Loffler M, Huber J, et al. Adipose tissue inflammation induced by high-fat diet in obese diabetic mice is prevented by n-3 polyunsaturated fatty acids. Diabetologia 2006; 49: 2109-19.
103. Moon Y, Pestka JJ. Deoxynivalenol-induced mitogen-activated protein kinase phosphorylation and IL-6 expression in mice suppressed by fish oil. J Nutr Biochem 2003; 14: 717-26.
104. Wang H, Hao Q, Li QR, et al. omega-3 Polyunsaturated fatty acids affect lipopolysaccharide-induced maturation of dendritic cells through mitogen-activated protein kinases p38. Nutrition 2007; 23: 474-82.
105. Zhang X, Zhou K, Wang R, et al. Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 2007; 282: 10873-80.